Northern Trust’s Ernexa Therapeutics ERNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-7
Closed -$12K – 4663
2022
Q3
$12K Hold
7
– – ﹤0.01% 4620
2022
Q2
$25K Sell
7
-26
-79% -$187K ﹤0.01% 4586
2022
Q1
$514K Sell
33
-3
-8% -$56.9K ﹤0.01% 3730
2021
Q4
$1.12M Buy
36
+1
+3% +$54.4K ﹤0.01% 3498
2021
Q3
$2.43M Buy
35
+4
+13% +$345K ﹤0.01% 3179
2021
Q2
$4.15M Buy
+31
New +$4.46M ﹤0.01% 2962
2016
Q2
– Hold
0
– -$4K – 4241
2016
Q1
– Hold
0
– – – 4202
2015
Q4
– Hold
0
– – – 4229
2015
Q3
– Hold
0
– – – 4224
2015
Q2
– Hold
0
– – – 4186
2015
Q1
– Hold
0
– – – 4248
2014
Q4
– Hold
0
– – – 4197
2014
Q3
– Hold
0
– – – 4233
2014
Q2
– Hold
0
– – – 4183
2014
Q1
– Hold
0
– – – 4109
2013
Q4
– Hold
0
– – – 4032
2013
Q3
– Hold
0
– – – 4015
2013
Q2
– Hold
0
– – – 4013

Other funds holding ERNA

Northern Trust's ERNA Position: Q4 2022 in Review

Northern Trust sold out of Ernexa Therapeutics (ERNA) in Q4 2022, closing a stake of 7 shares — an estimated $12K sold.

Northern Trust first reported a position in ERNA in Q2 2021 and held it in 6 quarters. The position peaked at $4.15M in Q2 2021. 11 funds tracked by Wall St. Rank hold ERNA as of Q4 2022.

  • Northern Trust reported no remaining Ernexa Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Northern Trust sold 7 Ernexa Therapeutics shares in Q4 2022, an estimated $12K.
  • Northern Trust first reported a position in Ernexa Therapeutics in Q2 2021 and held it in 6 quarters.
  • Northern Trust's Ernexa Therapeutics position peaked at $4.15M in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Ernexa Therapeutics as of Q4 2022.

Based on Northern Trust's 13F filing for Q4 2022, filed 13 Feb 2023.